Get the Stockscreener App
1.13
3.42%
-0.04
After Hours:
1.13
Can-Fite Biopharma Ltd ADR Stock (CANF) Forecast
The Can-Fite Biopharma Ltd ADR (CANF) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $32.84, representing a +2,807% increase from the current price of $1.13. The highest analyst price target is $33.84, and the lowest is $31.84.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month CANF Price Target
Average 25.64
(+2,169% Upside)
Is Can-Fite Biopharma Ltd ADR (CANF) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 35.45 | Neutral |
| STOCH(9,6) | 4.0413 | Buy |
| STOCHRSI(14) | 1.5316 | Buy |
| MACD(12,26) | -0.1066 | Sell |
| ADX(14) | 28.91 | Buy |
| William %R | -100.00 | Buy |
| CCI(14) | -77.47 | Neutral |
Buy: 4
Sell: 1
Neutral: 2
Summary: Buy
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.245
Sell
|
1.2325
Sell
|
| MA20 |
1.3428
Sell
|
1.3215
Sell
|
| MA50 |
1.5236
Sell
|
1.4572
Sell
|
| MA100 |
1.5499
Sell
|
1.6103
Sell
|
| MA200 |
2.0263
Sell
|
1.8171
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, CANF could be considered a Strong Sell, with 17 technical analysis indicators signaling 4 Buy signals, 11 signaling Sell signals and 2 Neutral signals. This might not be a good time to consider opening new positions on CANF, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 35.45 indicates that CANF is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 4.0413 indicates that CANF is oversold. This indicates that CANF price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 1.5316 indicates that CANF is oversold. This suggests that CANF price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 28.91 suggests a moderate trend in the market. While not exceptionally strong, it indicates that there is some directional movement occurring. You should pay attention to this trend but may also look for confirmation from other technical indicators or fundamental factors.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -77.47 indicates that CANF is still oversold but not to an extreme extent.
Long-term CANF price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Can-Fite Biopharma Ltd ADR financial reports and earnings history, Can-Fite Biopharma Ltd ADR (CANF) stock could reach $89.00 by 2030, $42.53 by 2040 and $128.59 by 2050. See the projected annual prices until 2050 of the Can-Fite Biopharma Ltd ADR stock below:
- Can-Fite Biopharma Ltd ADR (CANF) is expected to reach an average price of $13.21 in 2035, with a high prediction of $14.81 and a low estimate of $13.42. This indicates an $1,069% rise from the last recorded price of $1.13.
- Can-Fite Biopharma Ltd ADR (CANF) stock is projected to chart a bullish course in 2040, with an average price target of $41.54, representing an $3,576% surge from its current level. The forecast ranges from a conservative $41.60 to a sky-high $42.53.
- Our analysts predict Can-Fite Biopharma Ltd ADR (CANF) to jump 6,651% by 2045, soaring from $77.11 to an average price of $76.29, potentially reaching $77.02. While $77.11 is the low estimate, the potential upside is significant.
- Can-Fite Biopharma Ltd ADR (CANF) stock is expected to climb by 2050, reaching an average of $127.77, a $11,207% jump from its current level. However, a wide range of estimates exists, with high and low targets of $128.59 and $129.16, respectively, highlighting the market's uncertainty.
Can-Fite Biopharma Ltd ADR Stock (CANF) Year by Year Forecast
Can-Fite Biopharma Ltd ADR Stock (CANF) Price Forecast for 2025
Can-Fite Biopharma Ltd ADR Stock (CANF) is expected to reach an average price of $30.85 in 2025, with a high prediction of $39.36 and a low estimate of $22.35. This indicates an +2,630% rise from the last recorded price of $1.13.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2025 | $31.64 | $31.84 | $33.84 | +2,700% |
| June, 2025 | $30.64 | $31.94 | $30.95 | +2,612% |
| July, 2025 | $30.24 | $29.54 | $29.75 | +2,576% |
| August, 2025 | $29.04 | $28.34 | $28.46 | +2,470% |
| September, 2025 | $24.74 | $23.44 | $24.14 | +2,090% |
| October, 2025 | $29.34 | $23.64 | $22.97 | +2,497% |
| November, 2025 | $26.94 | $27.34 | $26.64 | +2,284% |
| December, 2025 | $26.34 | $26.34 | $26.54 | +2,231% |
Can-Fite Biopharma Ltd ADR Stock (CANF) Price Forecast for 2026
The predicted value for Can-Fite Biopharma Ltd ADR (CANF) in 2026 is set at an average of $19.29. Estimates vary from a peak of $25.14 to a trough of $13.44, indicating an +1,607% surge from the present price of $1.13.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $24.04 | $25.14 | $25.14 | +2,028% |
| February, 2026 | $23.64 | $23.84 | $23.04 | +1,992% |
| March, 2026 | $22.24 | $23.04 | $22.94 | +1,868% |
| April, 2026 | $16.74 | $17.44 | $20.74 | +1,381% |
| May, 2026 | $11.24 | $19.84 | $19.24 | +894.63% |
| June, 2026 | $14.84 | $14.84 | $14.24 | +1,213% |
| July, 2026 | $16.84 | $16.84 | $16.64 | +1,390% |
| August, 2026 | $14.34 | $16.14 | $15.14 | +1,169% |
| September, 2026 | $12.64 | $13.74 | $13.14 | +1,018% |
| October, 2026 | $13.84 | $13.44 | $13.69 | +1,125% |
| November, 2026 | $15.64 | $16.14 | $15.14 | +1,284% |
| December, 2026 | $16.64 | $16.39 | $16.04 | +1,372% |
Can-Fite Biopharma Ltd ADR Stock (CANF) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Can-Fite Biopharma Ltd ADR (CANF) is $16.78, with a high forecast of $19.04 and a low forecast of $14.53. This indicates an +1,385% increase from the last price of $1.13.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $17.04 | $16.94 | $16.44 | +1,408% |
| February, 2027 | $19.54 | $17.44 | $16.84 | +1,629% |
| March, 2027 | $17.93 | $19.84 | $19.04 | +1,487% |
| April, 2027 | $16.73 | $17.23 | $15.93 | +1,381% |
| May, 2027 | $17.73 | $17.63 | $17.53 | +1,469% |
| June, 2027 | $16.83 | $16.93 | $17.01 | +1,390% |
| July, 2027 | $14.83 | $16.03 | $16.83 | +1,213% |
| August, 2027 | $16.73 | $15.13 | $14.93 | +1,381% |
| September, 2027 | $16.44 | $16.93 | $16.61 | +1,354% |
| October, 2027 | $16.03 | $16.03 | $15.43 | +1,318% |
| November, 2027 | $14.83 | $15.43 | $14.83 | +1,213% |
| December, 2027 | $13.93 | $14.53 | $14.74 | +1,133% |
Can-Fite Biopharma Ltd ADR Stock (CANF) Price Forecast for 2028
In 2028, Can-Fite Biopharma Ltd ADR (CANF) is projected to reach an average price of $11.49, with a high projection of $13.49 and a low estimate of $9.4958. This indicates an +916.98% rise from the last price of $1.13.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $13.29 | $13.43 | $13.49 | +1,076% |
| February, 2028 | $13.53 | $13.13 | $13.33 | +1,097% |
| March, 2028 | $11.51 | $11.82 | $13.13 | +918.38% |
| April, 2028 | $10.71 | $11.43 | $11.12 | +847.63% |
| May, 2028 | $12.03 | $10.83 | $11.23 | +964.41% |
| June, 2028 | $12.80 | $12.40 | $11.71 | +1,033% |
| July, 2028 | $13.39 | $13.13 | $12.90 | +1,085% |
| August, 2028 | $13.35 | $13.38 | $13.32 | +1,081% |
| September, 2028 | $12.85 | $12.98 | $12.90 | +1,037% |
| October, 2028 | $12.12 | $12.52 | $12.76 | +972.27% |
| November, 2028 | $10.44 | $10.77 | $11.88 | +823.56% |
| December, 2028 | $9.3558 | $9.4958 | $10.06 | +727.95% |
Can-Fite Biopharma Ltd ADR Stock (CANF) Price Forecast for 2029
The 2029 price forecast for Can-Fite Biopharma Ltd ADR Stock (CANF) is $27.81 on average, with a high prediction of $55.40 and a low estimate of $0.2206. This represents an +2,361% increase from the previous price of $1.13.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $8.4053 | $8.4615 | $9.0057 | +643.83% |
| February, 2029 | $7.8749 | $8.1069 | $8.1352 | +596.89% |
| March, 2029 | $7.1645 | $7.2244 | $7.4749 | +534.03% |
| April, 2029 | $6.7441 | $6.8442 | $6.9144 | +496.82% |
| May, 2029 | $6.0836 | $6.1022 | $6.6013 | +438.37% |
| June, 2029 | $4.7832 | $4.9132 | $5.7335 | +323.29% |
| July, 2029 | $4.2228 | $4.3328 | $4.653 | +273.70% |
| August, 2029 | $3.3123 | $3.4823 | $3.9732 | +193.12% |
| September, 2029 | $2.5619 | $2.6219 | $3.0831 | +126.72% |
| October, 2029 | $1.3914 | $1.5835 | $2.2718 | +23.13% |
| November, 2029 | $0.841 | $0.881 | $1.1213 | -25.58% |
| December, 2029 | $58.76 | $0.2206 | $55.40 | +5,100% |
Can-Fite Biopharma Ltd ADR Stock (CANF) Price Forecast for 2030
Can-Fite Biopharma Ltd ADR Stock (CANF) is expected to reach an average price of $81.60 in 2030, with a high forecast of $92.00 and a low forecast of $71.20. This signifies an +7,121% surge from the last price of $1.13.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $91.20 | $71.20 | $89.00 | +7,971% |
| February, 2030 | $87.54 | $89.30 | $88.30 | +7,647% |
| March, 2030 | $88.80 | $88.00 | $85.80 | +7,758% |
| April, 2030 | $90.50 | $91.36 | $88.90 | +7,909% |
| May, 2030 | $92.20 | $90.90 | $92.00 | +8,059% |
| June, 2030 | $90.49 | $90.84 | $91.00 | +7,908% |
| July, 2030 | $82.59 | $86.19 | $86.53 | +7,209% |
| August, 2030 | $79.49 | $76.39 | $74.79 | +6,935% |
| September, 2030 | $78.89 | $76.09 | $73.53 | +6,882% |
| October, 2030 | $91.94 | $78.69 | $91.40 | +8,036% |
| November, 2030 | $88.26 | $89.99 | $88.24 | +7,711% |
| December, 2030 | $85.39 | $88.39 | $87.59 | +7,457% |
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):